ORAGENICS INC: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei ORAGENICS INC listata cu simbolurile US.OGEN, US.OGENc ==Descriere companie== Oragenics, Inc. (https://www.oragenics.com/) is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product c...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Oragenics, Inc. (https://www.oragenics.com/) is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile. | Oragenics, Inc. (https://www.oragenics.com/) is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and [[TERRA|Terra]] CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea de la data 2 octombrie 2024 14:16
Pagina dedicata companiei ORAGENICS INC listata cu simbolurile US.OGEN, US.OGENc
Descriere companie
Oragenics, Inc. (https://www.oragenics.com/) is a developing-stage company. The Company is focused on developing infectious diseases including coronaviruses and multidrug-resistant organisms. The Company’s pre-clinical product candidates includes OG716 and Terra CoV-2. It, through its subsidiary, is engaged in the research and development of Terra CoV-2 vaccine product candidate. It is also engaged in the development of its lead lantibiotic candidate, OG716, to treat Clostridium difficile.
Grafic actiuni companie